NCT05898477Recruiting
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
University of Alabama at Birmingham
Start Date
5/1/2023
Completion Date
7/1/2028
Summary
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Detailed Description
Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma
Eligibility Criteria
Age Range: No minimum to No maximum
Inclusion Criteria:
* Patients with lymphoma that are fulfilling at least one of the following:
A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25\>3,900 U/mL and ferritin\>1,000 ng/mL)
Exclusion Criteria:
* Patients developing HLH\> 1 month after lymphoma diagnosis (for aggressive lymphomas)
* Patients with incomplete treatment and response documentation
Conditions
LymphomaHemophagocytic Lymphohistiocytoses
Locations
University of Alabama at Birmingham
Birmingham, Alabama 35294
United States